NCT04209660View on ClinicalTrials.gov

Lenvatinib and Pembrolizumab in People With Advanced Adenoid Cystic Carcinoma and Other Salivary Gland Cancers

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

June 2, 2020

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
Adenoid Cystic CarcinomaSalivary Gland Cancer
Interventions
DRUG

Lenvatinib

Lenvatinib 20mg daily (two 10mg lenvatinib capsules) taken orally will be administered with water orally once a day (with or without food) in 21-day cycles at approximately the same time each day.

DRUG

Pembrolizumab

Pembrolizumab (200mg) will be administered as a 30-minute IV infusion, Q3W +/-3 days (infusions lasting between 25-40 minutes are acceptable on C1D1.

Trial Locations (8)

10065

Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York

10604

Memorial Sloan Kettering Westchester (All Protocol Activities), Harrison

11553

Memorial Sloan Kettering Nassau (All Protocol Activities), Uniondale

11725

Memorial Sloan Kettering Commack (All Protocol Activities), Commack

33143

Baptist Alliance MCI, Miami

07920

Memorial Sloan Kettering Basking Ridge (All Protocol Activities), Basking Ridge

07748

Memorial Sloan Kettering Monmouth (All protocol activities), Middletown

07645

Memorial Sloan Kettering Bergen (All Protocol Activities), Montvale

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

collaborator

Eisai Inc.

INDUSTRY

lead

Memorial Sloan Kettering Cancer Center

OTHER